Cannabics Pharmaceuticals, Inc. (CNBX)

downloadCannabics Pharmaceuticals, Inc. is a U.S.-based company focusing on the development of and commercialization of sophisticated, advanced medicines, food supplements, therapies, and administration routes based on cannabinoids, the active ingredients and naturally occurring compounds found in unique, diverse strains of the cannabis plant.

Through the Cannabic’s research and development extension laboratory located in Israel, the company is developing a pipeline of advanced therapies based on cannabinoids. Cannabics was founded in 2012 by a group of experienced researchers from the molecular biology, pharmacology, and cancer research fields. The company, through collaboration with key medical centers in the U.S., Europe, and Israel, is now launching clinical studies that investigate the beneficial effects of the company’s products in different medical indications.

The flagship product of Cannabics Pharmaceuticals, Inc. is Cannabics SR, a proprietary sustained release capsule containing medical cannabis. Cannabics SR is specially developed as a palliative care treatment for cancer patients. The medicine provides 10 to 12 hours of therapeutic effects on patients, allowing for once-a-day oral medical cannabis dosing regimen.

The Cannabics SR capsule contains pure concentrate of cannabinoids, which are extracted from selected strains of cannabis. The substances used in the sustained release formulation are certified food-grade, and the capsule is free of chemical substances or artificial additives.

Cannabics Pharmaceuticals, Inc. is an emerging company traded in the OTC markets under the stock symbol CNBX. The company develops their proprietary technologies in certified laboratories, and they license the utilization of such technologies to both manufacturers and distributors that have adequate licenses in their local territories.

Cannabics Pharmaceuticals, Inc. is not engaged in the manufacture, distribution, dispensing, or possession of any cannabis, cannabis-based preparations, and any other controlled substances. The company’s leaders are Dr. Zohar Koren, CEO and co-founder, and Dr. Eyal Ballan, CTO and co-founder.

Cannabics Pharmaceuticals, Inc.

#3 Bethesda Metro Center, Suite #700
Bethesda, MD 20814

Phone: (877) 424-2429
Email: info@cannabics.com
Website: http://www.cannabics.com/


Yahoo! Finance: CNBX News

Latest Financial News for CNBX

Cannabics Pharmaceuticals Announces Publication of Clinical Data From Its Sponsored Pilot Study on Controlled Release Capsules, on the Journal of Integrative Cancer Therapies

Data Demonstrated Cannabics' SR capsules with 5 mg dosage seems to be appropriate for the treatment of cancer anorexia-cachexia syndrome (CACS) in advanced cancer patients under active treatment. TEL AVIV, Israel and BETHESDA, Maryland, Oct. 16, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that the final results of its pilot study to test the efficacy of Cannabics' Dosage-Controlled capsules for the treatment of cancer anorexia-cachexia syndrome (CACS) in advanced cancer patients have been published on the Journal of Integrative Cancer Therapies.

Cannabics Pharmaceuticals Appoints Company's Founder to Its Board of Directors

TEL AVIV, Israel and BETHESDA, Maryland, Oct. 7, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabinoid based cancer medicine, today announced that it has appointed the Company's Founder as a new Director and Member of its Board. Itamar Borochov, 62, is an environmentalist with vast experience as an entrepreneur in the medical cannabis field, with broad experience in management and finance in medical cannabis companies which operate in regulated markets. Mr. Borochov was the original Founder of Cannabics Pharmaceuticals Inc.

Cannabics Pharmaceuticals to Present Research Data at the 2nd International Cannabinoid Derived Pharmaceuticals Summit in Boston, MA

TEL AVIV, Israel and BETHESDA, Maryland, Sept. 12, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX), a leader in personalized cannabis based cancer medicine, today announced that its Scientific Director, Dr. Ilan Hochman, is scheduled to present research data from cannabinoid tests on live cancer biopsies at the 2nd  International Cannabinoid Derived Pharmaceuticals Summit, to be held in Boston, MA, on September 10-12, 2019. The company has been focusing on developing solutions for bringing cannabis based solutions into the mainstream of cancer treatments together with existing therapeutic approaches.

'Algorithms Manage Everything': One Israeli Company's Mission To Make Marijuana Growing Effortless

Cannabis cultivation is a meticulous process that involves more than just planting a seed or a clone and watering it regularly. Luckily, there are solutions that make growing weed easier, even in the comfort of one’s home. One of these solutions is Seedo, a special pod that takes care of the entire growing process and can be controlled through an app on a smartphone.

Wize Pharma Completes Milestone for Joint Venture With Cannabics Pharmaceuticals; Companies to Develop Cannabinoid Ophthalmic Treatments

HOD HASHARON, Israel, June 28, 2019 /PRNewswire/ -- Wize Pharma, Inc. (WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced today that the Company and Cannabics Pharmaceuticals (CNBX) have together created and adopted a business plan for their joint venture (JV), a new entity focused on the research and development of cannabinoid formulations to treat ophthalmic conditions. Creation and approval of a business plan for the JV was a condition for the planned venture to move forward. Having assessed the regulatory pathway for eyedrops containing cannabinoids or cannabinoid strings, we are eagerly engaging in technology development and clinical advancement.